Global Bladder Cancer Therapeutics & Diagnostics Market - Expected to Grow 3-5% by 2020 - Research and Markets
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Global Clinical Trials Review, H1, 2016 - Research and Markets
Global Bile Duct Cancer (Cholangiocarcinoma) Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Sanofi, Novartis, Bayer - Research and Markets
Dow futures slide almost 100 points as Brexit fears keep nagging
MARKET SNAPSHOT: Dow Futures Slide Almost 100 Points As Brexit Fears Keep Nagging
Sanofi, Pfizer, Celgene may each pursue Medivation takeover
Brexit means little for biotech stocks, analyst says
Technavio Announces Top Ten Vendors in the Global Chronic Lymphocytic Leukemia Market from 2016 to 2020
If Americans sweep Democrats into office, these healthcare proposals could get a shot in the arm. Here’s how they would have an impact on earnings.
Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...